Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

FDA Bronchitol Approval to Generate Cash Flows for Pharmaxis
FDA Bronchitol Approval to Generate Cash Flows for Pharmaxis


It is the gold standard of success in biotech, but not many Australian companies can boast it – approval from the United States Food & Drug Administration (FDA) of a medicine you have researched

Kiadis Pharma: Kursgeschenke vor Übernahme?
Kiadis Pharma: Kursgeschenke vor Übernahme?

Die Aktie des niederländischen Pharmaforschers Kiadis (WKN: A14VE3) schießt heute um mehr als +200% in die Höhe. Kein Wunder: Mit Sanofi will ein Branchengigant die Firma schlucken.

Laut heutiger M

IMV Inc. to Report Third Quarter 2020 Results and Present Biomarkers Associated With Clinical Response in Patients With r/r DLBCL treated with DPX-Survivac Combination Therapy: https://mms.businesswire.com/media/20200225005324/en/775456/5/IMV_Logos_IMV-Logo_BrandStatement.jpg
IMV Inc. to Report Third Quarter 2020 Results and Present Biomarkers Associated With Clinical Response in Patients With r/r DLBCL treated with DPX-Survivac Combination Therapy


IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious

Sangamo Therapeutics Announces Third Quarter 2020 Conference Call and Webcast: https://mms.businesswire.com/media/20191101005100/en/736004/5/Sangamo_logoTM.jpg
Sangamo Therapeutics Announces Third Quarter 2020 Conference Call and Webcast


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its third quarter 2020 financial results after the market closes

Deciphera Pharmaceuticals, Inc. to Announce Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 5, 2020
Deciphera Pharmaceuticals, Inc. to Announce Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 5, 2020


Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that it will report its third quarter 2020 financial results on Thursday, November 5, 2020.



In connection with the earnings release

 
Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Xediton Pharmaceuticals
Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Xediton Pharmaceuticals

Quantum Genomics to receive up to $11.35 million in upfront and milestone payments plus double-digit royalties on sales

Xediton Pharmaceuticals to receive an exclusive license to develop and

Aurinia Announces European Investigator-Initiated Trial to Evaluate Antiviral Activity of Voclosporin in Kidney Transplant Recipients with COVID-19: https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
Aurinia Announces European Investigator-Initiated Trial to Evaluate Antiviral Activity of Voclosporin in Kidney Transplant Recipients with COVID-19


Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple indications

Transgene Announces Detailed Results From Clinical Study of TG4001 in Combination With Avelumab in Advanced HPV-positive Cancers: https://mms.businesswire.com/media/20191209005543/en/255636/5/logo_TRANSGENE.jpg
Transgene Announces Detailed Results From Clinical Study of TG4001 in Combination With Avelumab in Advanced HPV-positive Cancers


Regulatory News:



Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announced the detailed results from

CO.DON AG: Erste Spherox Transplantation in der Schweiz erfolgreich durchgeführt
CO.DON AG: Erste Spherox Transplantation in der Schweiz erfolgreich durchgeführt

 

Berlin / Teltow / Leipzig, 26.10.2020 Am Inselspital Bern, einem der führenden orthopädischen Zentren der Schweiz, wurde der erste Patient mit dem körpereigenen Knorpelzelltransplantat

Performance-Roundup: NBC-Empfehlung mit +543%; weitere Aktien im Fokus
Performance-Roundup: NBC-Empfehlung mit +543%; weitere Aktien im Fokus

Im Vorfeld der US-Präsidentschaftswahlen und mitten in der zweiten, voraussichtlich noch deutlich heftigeren Corona-Welle bleiben die Märkte erwartungsgemäß hochvolatil. Zwar hat die Pandemie bei

NANOBIOTIX Provides Updates on Global Clinical Development Plan for First-in-class Radioenhancer NBTXR3 at ASTRO 2020
NANOBIOTIX Provides Updates on Global Clinical Development Plan for First-in-class Radioenhancer NBTXR3 at ASTRO 2020


Regulatory News:


This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201026005205/en/



Pipeline Visualization (Photo: Business Wire)




NANO

Nanobiotix Announces Third Quarter 2020 Revenue : https://mms.businesswire.com/media/20191111005579/en/744572/5/LOGO_NANO_EXPANDING_LIFE.jpg
Nanobiotix Announces Third Quarter 2020 Revenue


Regulatory News:



NANOBIOTIX (Paris:NANO) (Euronext : NANO – ISIN : FR0011341205 – the ‘‘Company’’), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of

Aurinia Presents Voclosporin Efficacy and Pharmacokinetic Data from Integrated Analysis of AURA-LV and AURORA Pivotal Trials at ASN Kidney Week 2020: https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
Aurinia Presents Voclosporin Efficacy and Pharmacokinetic Data from Integrated Analysis of AURA-LV and AURORA Pivotal Trials at ASN Kidney Week 2020


Aurinia Pharmaceuticals Inc. (Nasdaq:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple indications

Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results: https://mms.businesswire.com/media/20191106005906/en/305625/5/puma_logo_JPEG.jpg
Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results


Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PST/4:30 p.m. EST on Thursday, Nov. 5, 2020, following the release of its third

 
BOIRON : Activity in the third quarter of 2020
BOIRON : Activity in the third quarter of 2020

October 22, 2020

ACTIVITY IN THE THIRD QUARTER OF 2020

(Unaudited data)

Cumulative activity as of the end of september 2020

In thousands of euros 2020 2019 Variation at current exchange
Navidea Biopharmaceuticals to Present at the Virtual Investor KOL Roundtable: https://mms.businesswire.com/media/20191107006076/en/389794/5/navidea_cmyk.jpg
Navidea Biopharmaceuticals to Present at the Virtual Investor KOL Roundtable


Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today

CO.DON AG: Prognose für 2020 bestätigt
CO.DON AG: Prognose für 2020 bestätigt

-          Leichtes Wachstum trotz Pandemie-Einflüssen

-          Weiterhin Wachstum im Gesamtjahresverlauf erwartet

 

Berlin / Teltow / Leipzig, 21.10.2020 Die CO.DON AG wird trotz der

Clovis Oncology to Announce Third Quarter 2020 Financial Results and Host Webcast Conference Call on November 5: https://mms.businesswire.com/media/20191107005162/en/305545/5/Clovis_Logo_Process_Color.jpg
Clovis Oncology to Announce Third Quarter 2020 Financial Results and Host Webcast Conference Call on November 5


Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its third quarter 2020 financial results on Thursday, November 5, 2020, before the open of the U.S. financial markets. Clovis’ senior management

NANOBIOTIX Announces Four Presentations at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting: https://mms.businesswire.com/media/20191111005579/en/744572/5/LOGO_NANO_EXPANDING_LIFE.jpg
NANOBIOTIX Announces Four Presentations at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting


Regulatory News:



NANOBIOTIX (Paris:NANO) (Euronext: NANO - ISIN: FR0011341205 – the “Company”), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today

Medigene AG: Medigene and Cytovant enter into service agreement for DC vaccine manufacturing process development
Medigene AG: Medigene and Cytovant enter into service agreement for DC vaccine manufacturing process development

 

Planegg/Martinsried (19.10.2020) - Medigene AG (MDG1, Frankfurt, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies for the

Medigene AG: Medigene und Cytovant schließen Servicevertrag zur Entwicklung eines Herstellungsverfahrens für DC-Impfstoffe ab
Medigene AG: Medigene und Cytovant schließen Servicevertrag zur Entwicklung eines Herstellungsverfahrens für DC-Impfstoffe ab

 

Planegg/Martinsried (19.10.2020) - Medigene AG (Medigene, FWB: MDG1, Prime Standard), ein Immunonkologie-Unternehmen mit klinischen Projekten fokussiert auf die Entwicklung

EnWave kündigt Aktienrückkaufprogramm an
EnWave kündigt Aktienrückkaufprogramm an

Vancouver, B.C., 19. Oktober 2020

 

EnWave Corporation (TSX-V:ENW | FSE:E4U) ("EnWave" oder das "Unternehmen" - https://www.commodity-tv.com/play/enwave-update-on-covid-19-impact-rev-machine

EnWave Announces Normal Course Issuer Bid
EnWave Announces Normal Course Issuer Bid

Vancouver, B.C., October 19, 2020

 

EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave,” or the "Company - https://www.commodity-tv.com/play/enwave-update-on-covid-19-impact-rev-machine-sales

Epigenomics: Aktie crasht -77% nach US-Schock
Epigenomics: Aktie crasht -77% nach US-Schock

Die staatliche US-Krankenversicherung Centers for Medicare & Medicaid Services (CMS) lehnt Epi proColon ab. Das geht aus einem vorläufigen Erstattungsvorschlag hervor. Die Schockwellen sind in der E

Transgene: Acceptance of Late Breaking Abstract at Upcoming SITC 2020 Conference, on The Detailed Results From Clinical Study of TG4001 in Combination With Avelumab in Advanced HPV-positive Cancers: https://mms.businesswire.com/media/20191209005543/en/255636/5/logo_TRANSGENE.jpg
Transgene: Acceptance of Late Breaking Abstract at Upcoming SITC 2020 Conference, on The Detailed Results From Clinical Study of TG4001 in Combination With Avelumab in Advanced HPV-positive Cancers


Regulatory News:



Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, announced that detailed results of the